Uveal melanoma

This phase 3 trial tests whether taking darovasertib and crizotinib after standard treatment can delay or prevent uveal melanoma from returning. The study enrolls adults with high-risk, non-metastatic uveal melanoma who have completed local therapy such as surgery or radiation. P…

This phase 2 trial is testing a drug called tebentafusp in 19 people with a rare eye cancer (uveal melanoma) that has spread to the liver. Participants receive weekly infusions for 6 months, then may have surgery to remove any remaining tumors. The goal is to see if the drug can …

This early-stage trial tests a personalized cell therapy called lifileucel for people with advanced uveal melanoma (a rare eye cancer) or certain sarcomas (connective tissue cancers). The treatment involves removing immune cells from the patient's tumor, growing them in a lab, an…

This study tests a drug called tebentafusp in people with a specific type of advanced eye cancer (uveal melanoma) that has spread to other parts of the body. The drug is designed to help the immune system attack cancer cells. Researchers will also use a blood test to measure tumo…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This study tests an experimental oral drug called VMD-102 in people with advanced solid tumors, including liver, lung, kidney, skin (uveal melanoma), and colorectal cancers that have not responded to standard treatments. The drug works by blocking a specific protein (PKC epsilon)…

This early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…

This study tests a drug called tebentafusp combined with treatments directed at the liver (like embolization or chemo-embolization) for people with a rare eye cancer (uveal melanoma) that has spread to the liver. About 109 adults with a specific immune type (HLA-A*0201) will part…

This early-phase trial tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) before eye removal surgery is safe and feasible for people with high-risk uveal melanoma, a rare eye cancer. Fifteen participants will receive the drugs, then have their eye removed. Th…

This phase 3 trial tests whether the drug tebentafusp can prevent uveal melanoma from coming back in high-risk patients after their initial treatment. About 290 people with a specific genetic marker (HLA-A*02:01) will either receive weekly infusions of tebentafusp or be observed …

This study tests a personalized treatment for advanced melanoma using a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), which are boosted with a protein called CD40L. After a short course of chemotherapy to make room, the enhanced cells are infused back a…

This early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor…

This early-phase study tests a new drug (IOV-3001) designed to boost immune cells in people with advanced melanoma that has not responded to prior treatments. About 42 adults will receive the drug alongside a personalized cell therapy called lifileucel. The main goals are to chec…

This study tests a drug called tebentafusp in 19 people with a rare eye cancer (uveal melanoma) that is too large to remove without taking the whole eye. The goal is to see if the drug can shrink the tumor by at least 20% so that less invasive surgery might be possible. Participa…

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…

This study tests a new treatment made from donor immune cells (CAR-NK cells) that are designed to attack two targets on melanoma cells. It is for adults with advanced melanoma that has spread or cannot be removed and has not responded to standard therapies. The goal is to find a …

This phase 3 trial tests darovasertib, a daily pill, given before standard local therapy (radiation or surgery) for people with uveal melanoma that hasn't spread. The goal is to see if the drug can prevent vision loss and avoid eye removal. About 520 participants will be randomly…

This early-stage trial tests whether adding a new drug called roginolisib to the existing treatment tebentafusp can help people with advanced uveal melanoma, a rare eye cancer. The study involves 8 adults whose cancer has spread and who are already on tebentafusp. The main goal i…

This study tests whether a new drug called RP2, given with nivolumab, works better than the current standard combination (ipilimumab plus nivolumab) for people with metastatic uveal melanoma, a rare eye cancer that has spread. About 280 adults who have not had prior immunotherapy…

This study tests a two-step treatment for people with a rare eye cancer (uveal melanoma) that has spread only to the liver. First, a chemotherapy drug is delivered directly to the liver through a special procedure. Then, an immunotherapy drug is given to help the immune system at…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer, and give them back after a short course of chemotherapy. T…

This study tests whether combining a targeted immunotherapy (tebentafusp) with a liver-directed radiation treatment (Y-90 radioembolization) can help control metastatic uveal melanoma that has spread to the liver. About 30 adults whose cancer is mainly in the liver and who have a…

This early-stage trial tests a new drug called ONM-501, which is injected directly into tumors, either alone or with the immunotherapy cemiplimab (Libtayo). The study includes 168 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The m…

This study tests whether two drugs, cemiplimab and ziv-aflibercept, can shrink or stop the growth of metastatic uveal melanoma, a rare eye cancer that has spread. About 32 adults with this condition will receive the combination treatment. The goal is to see if the drugs work bett…

This study tests an experimental drug called NBM-BMX in people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. The goal is to find the best dose, check for side effects, and see if the drug can shrink or slow tumors. Participants take…

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety in a small group of 10 patients. It is not a cure, but …

This early-stage trial tests a new drug called NN3201 in people with advanced cancers that have a specific marker called c-Kit. The drug is designed to deliver a chemotherapy agent directly to cancer cells, potentially killing them while sparing healthy tissue. The study will enr…

This phase 3 trial tests whether two different eye treatments can prevent vision loss in people who have had radiation therapy for a type of eye cancer called uveal melanoma. The study will compare faricimab injections given every 3 months, a fluocinolone acetonide implant placed…

This phase 2 trial tests whether the drug quisinostat can prevent uveal melanoma from spreading in high-risk patients. About 63 people who have completed initial treatment for their eye tumor will take quisinostat capsules three times a week. Researchers will track how long parti…

This study aims to find new genes that may cause a hereditary risk for uveal melanoma, a rare eye cancer. Researchers will analyze the DNA of 50 patients with this cancer to identify unknown genetic changes. The goal is to improve screening and surveillance for families affected …

This study looks at how the liver's immune system reacts to a chemotherapy drug called melphalan, given directly to the liver through a special procedure. It involves 10 adults with uveal melanoma that has spread to the liver. The goal is to understand immune changes, not to test…

This study is looking for 500 people with certain cancers (like eye or skin melanoma, kidney cancer, or mesothelioma) and their family members to understand how common BAP1 gene mutations are. Researchers will collect medical history and questionnaires to learn about cancer risks…

This study tracks how choroidal melanoma and its treatment affect patients' quality of life. It involves 15 people already in a larger Phase 3 trial. Participants fill out questionnaires about their well-being over two years. No new drugs or procedures are tested here.

This study follows 700 people with uveal melanoma, a rare eye cancer, who are at high risk of the cancer spreading to the liver. Participants get regular liver MRIs and blood tests to look for early signs of metastasis. The goal is to see if personalized monitoring can detect rel…